Search

Your search keyword '"Chanan-Khan, Asher"' showing total 1,732 results
Start Over Author "Chanan-Khan, Asher"
1,732 results on '"Chanan-Khan, Asher"'

2. Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial

Author

Byrd, John C, Hillmen, Peter, Ghia, Paolo, Kater, Arnon P, Chanan-Khan, Asher, Furman, Richard R, O'Brien, Susan, Yenerel, Mustafa Nuri, Illés, Arpad, Kay, Neil, Garcia-Marco, Jose A, Mato, Anthony, Pinilla-Ibarz, Javier, Seymour, John F, Lepretre, Stephane, Stilgenbauer, Stephan, Robak, Tadeusz, Rothbaum, Wayne, Izumi, Raquel, Hamdy, Ahmed, Patel, Priti, Higgins, Kara, Sohoni, Sophia, and Jurczak, Wojciech

Subjects
Clinical Research, Hematology, Lymphoma, Cancer, Rare Diseases, Clinical Trials and Supportive Activities, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Adenine, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Benzamides, Female, Follow-Up Studies, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Male, Middle Aged, Piperidines, Prognosis, Prospective Studies, Pyrazines, Survival Rate, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeAmong Bruton's tyrosine kinase inhibitors, acalabrutinib has greater selectivity than ibrutinib, which we hypothesized would improve continuous therapy tolerability. We conducted an open-label, randomized, noninferiority, phase III trial comparing acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia (CLL).MethodsPatients with previously treated CLL with centrally confirmed del(17)(p13.1) or del(11)(q22.3) were randomly assigned to oral acalabrutinib 100 mg twice daily or ibrutinib 420 mg once daily until progression or unacceptable toxicity. The primary end point was independent review committee-assessed noninferiority of progression-free survival (PFS).ResultsOverall, 533 patients (acalabrutinib, n = 268; ibrutinib, n = 265) were randomly assigned. At the data cutoff, 124 (46.3%) acalabrutinib patients and 109 (41.1%) ibrutinib patients remained on treatment. After a median follow-up of 40.9 months, acalabrutinib was determined to be noninferior to ibrutinib with a median PFS of 38.4 months in both arms (95% CI acalabrutinib, 33.0 to 38.6 and ibrutinib, 33.0 to 41.6; hazard ratio: 1.00; 95% CI, 0.79 to 1.27). All-grade atrial fibrillation/atrial flutter incidence was significantly lower with acalabrutinib versus ibrutinib (9.4% v 16.0%; P = .02); among other selected secondary end points, grade 3 or higher infections (30.8% v 30.0%) and Richter transformations (3.8% v 4.9%) were comparable between groups and median overall survival was not reached in either arm (hazard ratio, 0.82; 95% CI, 0.59 to 1.15), with 63 (23.5%) deaths with acalabrutinib and 73 (27.5%) with ibrutinib. Treatment discontinuations because of adverse events occurred in 14.7% of acalabrutinib-treated patients and 21.3% of ibrutinib-treated patients.ConclusionIn this first direct comparison of less versus more selective Bruton's tyrosine kinase inhibitors in CLL, acalabrutinib demonstrated noninferior PFS with fewer cardiovascular adverse events.

Published
2021

3. Daratumumab-lenalidomide and daratumumab-pomalidomide in relapsed lenalidomide-exposed or refractory multiple myeloma

Author

Alhaj Moustafa, Muhamad, Parrondo, Ricardo, Abdulazeez, Mays F., Roy, Vivek, Sher, Taimur, Alegria, Victoria R., Warsame, Rahma M., Fonseca, Rafael, Rasheed, Ahsan, Gonsalves, Wilson I., Kourelis, Taxiarchis, Kapoor, Prashant, Buadi, Francis K., Dingli, David, Hayman, Suzanne R., Reeder, Craig B., Chanan-Khan, Asher A., and Ailawadhi, Sikander

Published
2024
Full Text
View/download PDF

5. Updated efficacy and safety results of BCL-2 inhibitor lisaftoclax (APG-2575) alone or combined with ibrutinib or rituximab in patients (pts) with Waldenström macroglobulinemia (WM).

Author

Lasica, Masa, primary, Ailawadhi, Sikander, additional, Fu, Chengcheng, additional, Thomas, Sheeba K., additional, Wu, Depei, additional, Yi, Shuhua, additional, Siddiqi, Tanya, additional, Yin, Qingsong, additional, Allan, John N., additional, Chen, Wenming, additional, Matous, Jeffrey V, additional, Feng, Ru, additional, Chen, Zi, additional, Yu, Min, additional, Li, Mingyu, additional, He, Zicong, additional, Ahmad, Mohammad, additional, Wang, Hengbang, additional, Chanan-Khan, Asher Alban Akmal, additional, and Zhai, Yifan, additional

Published
2024
Full Text
View/download PDF

7. Second symptomatic COVID-19 infections in patients with an underlying monoclonal gammopathy

Author

Zanwar, Saurabh, Ho, Matthew, Buadi, Francis K., Ailawadhi, Sikander, Larsen, Jeremy, Bergsagel, Leif, Binder, Moritz, Chanan-Khan, Asher, Dingli, David, Dispenzieri, Angela, Fonseca, Rafael, Gertz, Morie A., Gonsalves, Wilson, Go, Ronald S., Hayman, Suzanne, Kapoor, Prashant, Kourelis, Taxiarchis, Lacy, Martha Q., Leung, Nelson, Lin, Yi, Muchtar, Eli, Roy, Vivek, Sher, Taimur, Warsame, Rahma, Fonder, Amie, Hobbs, Miriam, Hwa, Yi L., Kyle, Robert A., Vincent Rajkumar, S., and Kumar, Shaji

Published
2022
Full Text
View/download PDF

8. Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib

Author

Hampel, Paul J., Rabe, Kari G., Call, Timothy G., Ding, Wei, Leis, Jose F., Chanan-Khan, Asher A., Kenderian, Saad S., Muchtar, Eli, Wang, Yucai, Ailawadhi, Sikander, Koehler, Amber B., Parrondo, Ricardo, Schwager, Susan M., Sher, Taimur, Hanson, Curtis A., Shi, Min, Van Dyke, Daniel L., Braggio, Esteban, Slager, Susan L., Kay, Neil E., and Parikh, Sameer A.

Published
2022
Full Text
View/download PDF

10. Factors Determining Utilization of Stem Cell Transplant for Initial Therapy of Multiple Myeloma by Patient Race: Exploring Intra-racial Healthcare Disparities.

Author

Ailawadhi, Sikander, primary, Adu, Yaw, additional, Frank, Ryan, additional, Das, Saurav, additional, Hodge, David, additional, Fernandez, Andre, additional, Flott, Caitlyn, additional, Elliott, Jamie, additional, Parrondo, Ricardo, additional, Sher, Taimur, additional, Roy, Vivek, additional, and Chanan-Khan, Asher, additional

Published
2024
Full Text
View/download PDF

11. Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study

Author

Kelly, Kevin R, Ailawadhi, Sikander, Siegel, David S, Heffner, Leonard T, Somlo, George, Jagannath, Sundar, Zimmerman, Todd M, Munshi, Nikhil C, Madan, Sumit, Chanan-Khan, Asher, Lonial, Sagar, Chandwani, Suraj, Minasyan, Ashot, Ruehle, Markus, Barmaki-Rad, Farima, Abdolzade-Bavil, Afsaneh, Rharbaoui, Faiza, Herrmann-Keiner, Eva, Haeder, Thomas, Wartenberg-Demand, Andrea, and Anderson, Kenneth C

Published
2021
Full Text
View/download PDF

15. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes

Author

Archibald, William J., Rabe, Kari G., Kabat, Brian F., Herrmann, Joerg, Ding, Wei, Kay, Neil E., Kenderian, Saad S., Muchtar, Eli, Leis, Jose F., Wang, Yucai, Chanan-Khan, Asher A., Schwager, Susan M., Koehler, Amber B., Fonder, Amie L., Slager, Susan L., Shanafelt, Tait D., Call, Timothy G., and Parikh, Sameer A.

Published
2021
Full Text
View/download PDF

16. A phase II study of ibrutinib in combination with ixazomib in patients with Waldenström macroglobulinaemia.

Author

Parrondo, Ricardo D., Dutta, Navnita, LaPlant, Betsy R., Elliott, Jamie, Fernandez, Andre, Zimmerman, Ashley, Cicco, Gina, Han, Bing, Heslop, Keisha, Chapin, Dustin, Sher, Taimur, Roy, Vivek, Rasheed, Ahsan, Das, Saurav, Chanan‐Khan, Asher A., Paulus, Aneel, and Ailawadhi, Sikander

Subjects
BRUTON tyrosine kinase, PROGRESSION-free survival
Abstract

Summary: This phase II study evaluated time‐limited (24 cycles) treatment with ibrutinib and ixazomib in newly diagnosed (NDWM; n = 9) and relapsed/refractory (RRWM; n = 12) Waldenström macroglobulinaemia (WM). The overall response rate (ORR) was 76.2% (n = 16) in 21 evaluable patients with no patient achieving a complete response (CR). The median duration of treatment was 15.6 months, and after a median follow‐up time of 25.7 months, the median progression‐free survival (PFS) was 22.9 months. While the primary end‐point was not met (CR rate at any time) and 28.5% discontinued treatment due to toxicity, ibrutinib plus ixazomib led to a clinically meaningful ORR and PFS. Combined Bruton's tyrosine kinase (BTK) and proteasome inhibition merits further evaluation in WM. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial*

Author

Wendtner, Clemens M, Hallek, Michael, Fraser, Graeme AM, Michallet, Anne-Sophie, Hillmen, Peter, Dürig, Jan, Kalaycio, Matt, Gribben, John G, Stilgenbauer, Stephan, Buhler, Andreas, Kipps, Thomas J, Purse, Brendan, Zhang, Jennie, De Bedout, Sabine, Mei, Jay, and Chanan-Khan, Asher

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Clinical Research, Clinical Trials and Supportive Activities, Patient Safety, Hematology, Lymphoma, Rare Diseases, Cancer, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Drug Resistance, Neoplasm, Female, Humans, Immunologic Factors, Kaplan-Meier Estimate, Lenalidomide, Leukemia, Lymphocytic, Chronic, B-Cell, Male, Middle Aged, Neoplasm Staging, Recurrence, Retreatment, Thalidomide, Treatment Outcome, Clinical trial, CLL, lenalidomide, phase II, Clinical Sciences, Immunology, Cardiovascular medicine and haematology
Abstract

The objective of this study was to evaluate the safety and efficacy of different lenalidomide starting doses in patients with relapsed/refractory chronic lymphocytic leukemia (CLL). CLL patients were randomized to receive lenalidomide at initial doses of 5, 10, or 15 mg/d (N = 103). Doses were escalated by 5 mg every 28-d up to a maximum of 25 mg/d; dose reductions in up to 5 mg decrements were permitted. The most common grade ≥3 adverse events (AEs) were neutropenia and thrombocytopenia. Ten patients died during therapy (four deaths considered as related to lenalidomide); 12 patients experienced second primary malignancies. The most common cause for treatment discontinuation was AEs. Overall response rates were similar across arms. Progression-free survival and overall survival rates were longer in patients who escalated treatment (to 15 or 20 mg/d) versus those who did not. Lower starting doses allowed subsequent dose escalation of lenalidomide while maintaining an acceptable tolerability profile in patients with relapsed/refractory CLL.

Published
2016

19. MicroRNA and long non-coding RNA analysis in IgM monoclonal gammopathies reveals epigenetic influence on cellular functions and oncogenesis

Author

Chohan, Karan, primary, Paludo, Jonas, additional, Dasari, Surendra, additional, Mondello, Patrizia, additional, Novak, Joseph P, additional, Abeykoon, Jithma P., additional, Wenzl, Kerstin, additional, Yang, Zhi-Zhang, additional, Jalali, Shahrzad, additional, Krull, Jordan E, additional, Braggio, Esteban, additional, Manske, Michelle K., additional, Paulus, Aneel, additional, Reeder, Craig B., additional, Ailawadhi, Sikander, additional, Chanan-Khan, Asher, additional, Kapoor, Prashant, additional, Kyle, Robert A., additional, Gertz, Morie A, additional, Novak, Anne J., additional, and Ansell, Stephen M., additional

Published
2023
Full Text
View/download PDF

20. Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia

Author

Kipps, Thomas J., Fraser, Graeme, Coutre, Steven E., Brown, Jennifer R., Barrientos, Jacqueline C., Barr, Paul M., Byrd, John C., O’Brien, Susan M., Dilhuydy, Marie-Sarah, Hillmen, Peter, Jaeger, Ulrich, Moreno, Carol, Cramer, Paula, Stilgenbauer, Stephan, Chanan-Khan, Asher A., Mahler, Michelle, Salman, Mariya, Eckert, Karl, Solman, Isabelle G., Balasubramanian, Sriram, Cheng, Mei, Londhe, Anil, Ninomoto, Joi, Howes, Angela, James, Danelle F., and Hallek, Michael

Published
2019
Full Text
View/download PDF

23. In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.

Author

Tefferi, Ayalew, Kantarjian, Hagop, Rajkumar, S Vincent, Baker, Lawrence H, Abkowitz, Jan L, Adamson, John W, Advani, Ranjana Hira, Allison, James, Antman, Karen H, Bast, Robert C, Bennett, John M, Benz, Edward J, Berliner, Nancy, Bertino, Joseph, Bhatia, Ravi, Bhatia, Smita, Bhojwani, Deepa, Blanke, Charles D, Bloomfield, Clara D, Bosserman, Linda, Broxmeyer, Hal E, Byrd, John C, Cabanillas, Fernando, Canellos, George Peter, Chabner, Bruce A, Chanan-Khan, Asher, Cheson, Bruce, Clarkson, Bayard, Cohn, Susan L, Colon-Otero, Gerardo, Cortes, Jorge, Coutre, Steven, Cristofanilli, Massimo, Curran, Walter J, Daley, George Q, DeAngelo, Daniel J, Deeg, H Joachim, Einhorn, Lawrence H, Erba, Harry P, Esteva, Francisco J, Estey, Elihu, Fidler, Isaiah J, Foran, James, Forman, Stephen, Freireich, Emil, Fuchs, Charles, George, James N, Gertz, Morie A, Giralt, Sergio, Golomb, Harvey, Greenberg, Peter, Gutterman, Jordan, Handin, Robert I, Hellman, Samuel, Hoff, Paulo Marcelo, Hoffman, Ronald, Hong, Waun Ki, Horowitz, Mary, Hortobagyi, Gabriel N, Hudis, Clifford, Issa, Jean Pierre, Johnson, Bruce Evan, Kantoff, Philip W, Kaushansky, Kenneth, Khayat, David, Khuri, Fadlo R, Kipps, Thomas J, Kripke, Margaret, Kyle, Robert A, Larson, Richard A, Lawrence, Theodore S, Levine, Ross, Link, Michael P, Lippman, Scott M, Lonial, Sagar, Lyman, Gary H, Markman, Maurie, Mendelsohn, John, Meropol, Neal J, Messinger, Yoav, Mulvey, Therese M, O'Brien, Susan, Perez-Soler, Roman, Pollock, Raphael, Prchal, Josef, Press, Oliver, Radich, Jerald, Rai, Kanti, Rosenberg, Saul A, Rowe, Jacob M, Rugo, Hope, Runowicz, Carolyn D, Sandmaier, Brenda M, Saven, Alan, Schafer, Andrew I, Schiffer, Charles, Sekeres, Mikkael A, Silver, Richard T, Siu, Lillian L, and Steensma, David P

Subjects
Humans, Neoplasms, Antineoplastic Agents, Patient Advocacy, Patient Participation, Drug Costs, Prescription Fees, United States, Medical and Health Sciences
Published
2015

26. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

Author

Nicol, Andrew, Grigoriadis, George, Catalano, John, LeBlanc, Richard, Elemary, Mohamed, Bahlis, Nizar, Facon, Thierry, Karlin, Lionel, Ribrag, Vincent, Attal, Michel, Goldschmidt, Hartmut, Engelhardt, Monika, Weisel, Katja, Mackensen, Andreas, Nagler, Arnon, Ben Yehuda, Dina, Avivi, Irit, Benyamini, Noam, Magen-Nativ, Hila, Palumbo, Antonio, Cavo, Michele, Tobinai, Kensei, Iida, Shinsuke, Chou, Takaai, Suzuki, Kenshi, Kosugi, Hiroshi, Taniwaki, Masafumi, Sunami, Kazutaka, Matsumoto, Morio, Ando, Kiyoshi, Ganly, Peter, Blacklock, Hilary, Simpson, David, George, Anupkumar, Schjesvold, Fredrik, Gjertsen, Bjorn, Lahuerta, Juan, Blade, Joan, Oriol Rocafiguera, Albert, Mateos, Maria, Rodriguez-Otero, Paula, Larson, Sarah, Atanackovic, Djordje, Devarakonda, Srinivas, Bitran, Jacob, Zonder, Jeffrey, Morganstein, Neil, Hay, Mohammad, Chanan-Khan, Asher, Saylors, Gene, Kio, Ebenezer, Oliff, Ira, Kirkel, Dean, Shtivelband, Mikhail, Yuen, Carrie, Yee, Andrew, Shah, Jatin, Htut, Myo, Raza, Shahzad, Chhabra, Saurabh, Stiff, Patrick, Hari, Parameswaran, Bank, Bruce, Malek, Ehsan, Gasparetto, Cristina, Faroun, Ycaoub, Sherbenou, Daniel, Kreisle, William, Singhal, Seema, Rosenblatt, Jacalyn, Usmani, Saad, Lee, Wes, Safah, Hana, Lutzky, Jose, Suh, Jason, Pan, Dorothy, Baron, Ari, Manges, Robert, Steis, Ronald, Oliveira, Moacyr, Moreb, Jan, Callander, Natalie, Anz, Bertrand, Raptis, Anastasios, Stampleman, Laura, Melear, Jason, Boyd, Thomas, Garbo, Lawrence, Klein, Leonard, Shao, Spencer, Lyons, Roger, McIntyre, Kristi, Tarantolo, Stefano, Yasenchak, Christopher, Yimer, Habte, Mateos, Maria-Victoria, Oriol, Albert, Larocca, Alessandra, Usmani, Saad Z, Jagannath, Sundar, Ocio, Enrique M, San Miguel, Jesus, Kher, Uma, Farooqui, Mohammed, Liao, Jason, Marinello, Patricia, and Lonial, Sagar

Published
2019
Full Text
View/download PDF

27. Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations

Author

Soumerai, Jacob D, Ni, Ai, Darif, Mohamed, Londhe, Anil, Xing, Guan, Mun, Yong, Kay, Neil E, Shanafelt, Tait D, Rabe, Kari G, Byrd, John C, Chanan-Khan, Asher A, Furman, Richard R, Hillmen, Peter, Jones, Jeffrey, Seymour, John F, Sharman, Jeffrey P, Ferrante, Lucille, Mobasher, Mehrdad, Stark, Thomas, Reddy, Vijay, Dreiling, Lyndah K, Bhargava, Pankaj, Howes, Angela, James, Danelle F, and Zelenetz, Andrew D

Published
2019
Full Text
View/download PDF

31. Daratumumab-lenalidomide and daratumumab-pomalidomide in relapsed lenalidomide-exposed or refractory multiple myeloma.

Author

Moustafa, Muhamad Alhaj, Parrondo, Ricardo, Abdulazeez, Mays F., Roy, Vivek, Sher, Taimur, Alegria, Victoria R., Warsame, Rahma M., Fonseca, Rafael, Rasheed, Ahsan, Gonsalves, Wilson I., Kourelis, Taxiarchis, Kapoor, Prashant, Buadi, Francis K., Dingli, David, Hayman, Suzanne R., Reeder, Craig B., Chanan-Khan, Asher A., and Ailawadhi, Sikander

Published
2024
Full Text
View/download PDF

32. POSTER: IBCL-597 Micro-RNAs as Epigenetic Regulators of Cytokine Signaling Pathways and the Tumor Microenvironment in Waldenström Macroglobulinemia Compared to IgM-MGUS

Author

Chohan, Karan, primary, Paludo, Jonas, additional, Dasari, Surendra, additional, Mondello, Patrizia, additional, Novak, Joseph, additional, Abeykoon, Jithma, additional, Wenzl, Kerstin, additional, Yang, Zhi-Zhang, additional, Jalali, Shahrzad, additional, Krull, Jordan, additional, Braggio, Esteban, additional, Manske, Michelle, additional, Paulus, Aneel, additional, Reeder, Craig, additional, Ailawadhi, Sikander, additional, Chanan-Khan, Asher, additional, Kapoor, Prashant, additional, Kyle, Robert, additional, Gertz, Morie, additional, Novak, Anne, additional, and Ansell, Stephen, additional

Published
2023
Full Text
View/download PDF

33. IBCL-597 Micro-RNAs as Epigenetic Regulators of Cytokine Signaling Pathways and the Tumor Microenvironment in Waldenström Macroglobulinemia Compared to IgM-MGUS

Author

Chohan, Karan, primary, Paludo, Jonas, additional, Dasari, Surendra, additional, Mondello, Patrizia, additional, Novak, Joseph, additional, Abeykoon, Jithma, additional, Wenzl, Kerstin, additional, Yang, Zhi-Zhang, additional, Jalali, Shahrzad, additional, Krull, Jordan, additional, Braggio, Esteban, additional, Manske, Michelle, additional, Paulus, Aneel, additional, Reeder, Craig, additional, Ailawadhi, Sikander, additional, Chanan-Khan, Asher, additional, Kapoor, Prashant, additional, Kyle, Robert, additional, Gertz, Morie, additional, Novak, Anne, additional, and Ansell, Stephen, additional

Published
2023
Full Text
View/download PDF

34. The digital divide: Racial disparities in adoption and utilization of health information technology among patients with lymphoid cancers

Author

Ailawadhi, Sikander, primary, Ailawadhi, Meghna, additional, Dutta, Navnita, additional, Parrondo, Ricardo D., additional, Roy, Vivek, additional, Sher, Taimur, additional, Baksh, Mizba, additional, Rasheed, Ahsan, additional, Das, Saurav, additional, Fernandez, Andre J., additional, Paulus, Aneel, additional, and Chanan‐Khan, Asher A., additional

Published
2023
Full Text
View/download PDF

35. Supplementary Figures S1-S7 from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial

Author

Ailawadhi, Sikander, primary, Chen, Zi, primary, Huang, Bo, primary, Paulus, Aneel, primary, Collins, Mary C., primary, Fu, Lei (Tommy), primary, Li, Mingyu, primary, Ahmad, Mohammad, primary, Men, Lichuang, primary, Wang, Hengbang, primary, Davids, Matthew S., primary, Liang, Eric, primary, Mekala, Divya J., primary, He, Zhicong, primary, Lasica, Masa, primary, Yannakou, Costas K., primary, Parrondo, Ricardo, primary, Glass, Laura, primary, Yang, Dajun, primary, Chanan-Khan, Asher, primary, and Zhai, Yifan, primary

Published
2023
Full Text
View/download PDF

36. Table S1 from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial

Author

Ailawadhi, Sikander, primary, Chen, Zi, primary, Huang, Bo, primary, Paulus, Aneel, primary, Collins, Mary C., primary, Fu, Lei (Tommy), primary, Li, Mingyu, primary, Ahmad, Mohammad, primary, Men, Lichuang, primary, Wang, Hengbang, primary, Davids, Matthew S., primary, Liang, Eric, primary, Mekala, Divya J., primary, He, Zhicong, primary, Lasica, Masa, primary, Yannakou, Costas K., primary, Parrondo, Ricardo, primary, Glass, Laura, primary, Yang, Dajun, primary, Chanan-Khan, Asher, primary, and Zhai, Yifan, primary

Published
2023
Full Text
View/download PDF

38. Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM

Author

Moreau, Philippe, Chanan-Khan, Asher, Roberts, Andrew W., Agarwal, Amit B., Facon, Thierry, Kumar, Shaji, Touzeau, Cyrille, Punnoose, Elizabeth A., Cordero, Jaclyn, Munasinghe, Wijith, Jia, Jia, Salem, Ahmed Hamed, Freise, Kevin J., Leverson, Joel D., Enschede, Sari Heitner, Ross, Jeremy A., Maciag, Paulo C., Verdugo, Maria, and Harrison, Simon J.

Published
2017
Full Text
View/download PDF

40. Multiomics analysis in IgM monoclonal gammopathies reveals epigenetic influence on oncogenesis via DNA methylation

Author

Chohan, Karan, Paludo, Jonas, Dasari, Surendra, Mondello, Patrizia, Novak, Joseph P., Abeykoon, Jithma P., Wenzl, Kerstin, Yang, Zhi-Zhang, Jalali, Shahrzad, Bhardwaj, Vaishali, Krull, Jordan E., Braggio, Esteban, Manske, Michelle K., Paulus, Aneel, Reeder, Craig B., Ailawadhi, Sikander, Chanan-Khan, Asher, Kapoor, Prashant, Kyle, Robert A., Gertz, Morie A., Novak, Anne J., and Ansell, Stephen M.

Published
2024
Full Text
View/download PDF

41. Data from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial

Author

Ailawadhi, Sikander, primary, Chen, Zi, primary, Huang, Bo, primary, Paulus, Aneel, primary, Collins, Mary C., primary, Fu, Lei (Tommy), primary, Li, Mingyu, primary, Ahmad, Mohammad, primary, Men, Lichuang, primary, Wang, Hengbang, primary, Davids, Matthew S., primary, Liang, Eric, primary, Mekala, Divya J., primary, He, Zhicong, primary, Lasica, Masa, primary, Yannakou, Costas K., primary, Parrondo, Ricardo, primary, Glass, Laura, primary, Yang, Dajun, primary, Chanan-Khan, Asher, primary, and Zhai, Yifan, primary

Published
2023
Full Text
View/download PDF

42. Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial

Author

Ailawadhi, Sikander, primary, Chen, Zi, additional, Huang, Bo, additional, Paulus, Aneel, additional, Collins, Mary C., additional, Fu, Lei (Tommy), additional, Li, Mingyu, additional, Ahmad, Mohammad, additional, Men, Lichuang, additional, Wang, Hengbang, additional, Davids, Matthew S., additional, Liang, Eric, additional, Mekala, Divya J., additional, He, Zhicong, additional, Lasica, Masa, additional, Yannakou, Costas K., additional, Parrondo, Ricardo, additional, Glass, Laura, additional, Yang, Dajun, additional, Chanan-Khan, Asher, additional, and Zhai, Yifan, additional

Published
2023
Full Text
View/download PDF

43. Daratumumab-lenalidomide and daratumumab-pomalidomide in relapsed lenalidomide-exposed or refractory multiple myeloma

Author

Alhaj Moustafa, Muhamad, primary, Parrondo, Ricardo, additional, Abdulazeez, Mays F., additional, Roy, Vivek, additional, Sher, Taimur, additional, Alegria, Victoria R., additional, Warsame, Rahma M., additional, Fonseca, Rafael, additional, Rasheed, Ahsan, additional, Gonsalves, Wilson I., additional, Kourelis, Taxiarchis, additional, Kapoor, Prashant, additional, Buadi, Francis K., additional, Dingli, David, additional, Hayman, Suzanne R., additional, Reeder, Craig B., additional, Chanan-Khan, Asher A., additional, and Ailawadhi, Sikander, additional

Published
2023
Full Text
View/download PDF

46. Supplementary Figures from Lisaftoclax (APG-2575) Is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic Malignancy

Author

Deng, Jing, primary, Paulus, Aneel, primary, Fang, Douglas D., primary, Manna, Alak, primary, Wang, Guangfeng, primary, Wang, Hengbang, primary, Zhu, Saijie, primary, Chen, Jianyong, primary, Min, Ping, primary, Yin, Yan, primary, Dutta, Navnita, primary, Halder, Nabanita, primary, Ciccio, Gina, primary, Copland, John A., primary, Miller, James, primary, Han, Bing, primary, Bai, Longchuan, primary, Liu, Liu, primary, Wang, Mi, primary, McEachern, Donna, primary, Przybranowski, Sally, primary, Yang, Chao-Yie, primary, Stuckey, Jeanne A., primary, Wu, Depei, primary, Li, Caixia, primary, Ryan, Jeremy, primary, Letai, Anthony, primary, Ailawadhi, Sikander, primary, Yang, Dajun, primary, Wang, Shaomeng, primary, Chanan-Khan, Asher, primary, and Zhai, Yifan, primary

Published
2023
Full Text
View/download PDF

47. Supplementary Tables from Lisaftoclax (APG-2575) Is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic Malignancy

Author

Deng, Jing, primary, Paulus, Aneel, primary, Fang, Douglas D., primary, Manna, Alak, primary, Wang, Guangfeng, primary, Wang, Hengbang, primary, Zhu, Saijie, primary, Chen, Jianyong, primary, Min, Ping, primary, Yin, Yan, primary, Dutta, Navnita, primary, Halder, Nabanita, primary, Ciccio, Gina, primary, Copland, John A., primary, Miller, James, primary, Han, Bing, primary, Bai, Longchuan, primary, Liu, Liu, primary, Wang, Mi, primary, McEachern, Donna, primary, Przybranowski, Sally, primary, Yang, Chao-Yie, primary, Stuckey, Jeanne A., primary, Wu, Depei, primary, Li, Caixia, primary, Ryan, Jeremy, primary, Letai, Anthony, primary, Ailawadhi, Sikander, primary, Yang, Dajun, primary, Wang, Shaomeng, primary, Chanan-Khan, Asher, primary, and Zhai, Yifan, primary

Published
2023
Full Text
View/download PDF

48. Supplementary Data from Lisaftoclax (APG-2575) Is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic Malignancy

Author

Deng, Jing, primary, Paulus, Aneel, primary, Fang, Douglas D., primary, Manna, Alak, primary, Wang, Guangfeng, primary, Wang, Hengbang, primary, Zhu, Saijie, primary, Chen, Jianyong, primary, Min, Ping, primary, Yin, Yan, primary, Dutta, Navnita, primary, Halder, Nabanita, primary, Ciccio, Gina, primary, Copland, John A., primary, Miller, James, primary, Han, Bing, primary, Bai, Longchuan, primary, Liu, Liu, primary, Wang, Mi, primary, McEachern, Donna, primary, Przybranowski, Sally, primary, Yang, Chao-Yie, primary, Stuckey, Jeanne A., primary, Wu, Depei, primary, Li, Caixia, primary, Ryan, Jeremy, primary, Letai, Anthony, primary, Ailawadhi, Sikander, primary, Yang, Dajun, primary, Wang, Shaomeng, primary, Chanan-Khan, Asher, primary, and Zhai, Yifan, primary

Published
2023
Full Text
View/download PDF

49. Supplementary Figure 3 from Molecular Clusters and Tumor-Immune Drivers of IgM Monoclonal Gammopathies

Author

Mondello, Patrizia, primary, Paludo, Jonas, primary, Novak, Joseph P., primary, Wenzl, Kerstin, primary, Yang, Zhi-Zhang, primary, Jalali, Shahrzad, primary, Krull, Jordan E., primary, Braggio, Esteban, primary, Dasari, Surendra, primary, Manske, Michelle K., primary, Abeykoon, Jithma A., primary, Sarangi, Vivekananda, primary, Kapoor, Prashant, primary, Paulus, Aneel, primary, Reeder, Craig B., primary, Ailawadhi, Sikander, primary, Chanan-Khan, Asher A., primary, Kyle, Robert A., primary, Gertz, Morie A., primary, Novak, Anne J., primary, and Ansell, Stephen M., primary

Published
2023
Full Text
View/download PDF

50. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma

Author

Paludo, Jonas, Mikhael, Joseph R., LaPlant, Betsy R., Halvorson, Alese E., Kumar, Shaji, Gertz, Morie A., Hayman, Suzanne R., Buadi, Francis K., Dispenzieri, Angela, Lust, John A., Kapoor, Prashant, Leung, Nelson, Russell, Stephen J., Dingli, David, Go, Ronald S., Lin, Yi, Gonsalves, Wilson I., Fonseca, Rafael, Bergsagel, P.Leif, Roy, Vivek, Sher, Taimur, Chanan-Khan, Asher A., Ailawadhi, Sikander, Stewart, A.Keith, Reeder, Craig B., Richardson, Paul G., Rajkumar, S.Vincent, and Lacy, Martha Q.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results